Viking Therapeutics Files 8-K Report
Ticker: VKTX · Form: 8-K · Filed: Aug 19, 2025 · CIK: 1607678
Sentiment: neutral
Topics: 8-K, disclosure, financials
Related Tickers: VKTX
TL;DR
Viking Therapeutics (VKTX) filed an 8-K on Aug 19, 2025, for Reg FD disclosure & financials.
AI Summary
On August 19, 2025, Viking Therapeutics, Inc. filed an 8-K report. The filing primarily serves as a notification of a Regulation FD Disclosure and includes Financial Statements and Exhibits. No specific material events or financial figures were detailed in the provided excerpt.
Why It Matters
This filing indicates Viking Therapeutics is making a disclosure under Regulation FD, which could contain material information for investors. The inclusion of financial statements and exhibits suggests updates or required filings related to the company's financial status.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain specific material events, financial data, or forward-looking statements that would indicate a high or medium risk.
Key Players & Entities
- Viking Therapeutics, Inc. (company) — Registrant
- August 19, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 46-1073877 (identifier) — IRS Employer Identification No.
- 9920 Pacific Heights Blvd, Suite 350 (address) — Principal Executive Offices
- San Diego, California (location) — Principal Executive Offices City and State
- 92121 (zip_code) — Principal Executive Offices Zip Code
- 858 704-4660 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing by Viking Therapeutics?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to include Financial Statements and Exhibits, as indicated by the filing details for August 19, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on August 19, 2025.
What is Viking Therapeutics, Inc.'s state of incorporation?
Viking Therapeutics, Inc. is incorporated in Delaware.
What is the business address of Viking Therapeutics, Inc.?
The business address of Viking Therapeutics, Inc. is 9920 Pacific Heights Blvd, Suite 350, San Diego, California, 92121.
What is the IRS Employer Identification Number for Viking Therapeutics, Inc.?
The IRS Employer Identification Number for Viking Therapeutics, Inc. is 46-1073877.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-08-19 07:09:43
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share VKTX The Nasdaq Stock Mar
Filing Documents
- vktx-20250819.htm (8-K) — 44KB
- vktx-ex99_1.htm (EX-99.1) — 136KB
- img201808844_0.jpg (GRAPHIC) — 10KB
- gfx201808844_0.jpg (GRAPHIC) — 4KB
- 0001607678-25-000003.txt ( ) — 318KB
- vktx-20250819.xsd (EX-101.SCH) — 24KB
- vktx-20250819_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 19, 2025, Viking Therapeutics, Inc. issued a press release announcing top-line results from the Company's Phase 2 clinical trial of the oral tablet formulation of VK2735. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information furnished under this Item 7.01 (Regulation FD Disclosure) of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated August 19, 2025. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIKING THERAPEUTICS, INC. Date: August 19, 2025 By: /s/ Brian Lian, Ph.D. Brian Lian, Ph.D. President and Chief Executive Officer ( Principal Executive Officer )